Evidence map›Paper›PMID 31650358›Full record

ArticleAIDS and behavior2020

Evaluating Measures of Pre-ART Adherence Readiness Through Associations with ART Adherence in the Early Months of Treatment.

Gulrez Shah Azhar, Stefan Schneider, Risa Hoffman, Kyle Gordon, Daniel Ramirez, Glenn Wagner

Abstract read
In one paragraph

Article in AIDS and behavior, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gulrez Shah AzharPardee RAND Graduate School, 1776 Main Street, Santa Monica, CA, 90401, USA. gazhar@rand.org.
Stefan SchneiderLong Beach Education and Research Consultants, Long Beach, CA, USA.
Risa HoffmanDivision of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA.
Kyle GordonDivision of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA.
Daniel RamirezLong Beach Education and Research Consultants, Long Beach, CA, USA.
Glenn WagnerThe RAND Corporation, 1776 Main Street, Santa Monica, CA, 90401, USA.

Funding

Controlled Evaluation of the Adherence Readiness Program for ART AdherenceR01MH104086 · NIMH · RAND CORPORATION · PI WAGNER, GLENN JOHN · 2015 to 2019
$2.8M
National Institute of Mental Health (US) R01MH104086NIMH NIH HHS R01 MH104086
6 · The paper itself

Abstract

Determining a patient's readiness to adhere well prior to the start of ART provides an opportunity to address adherence barriers before poor pill taking habits form, and ultimately improve clinical outcomes and resource utilization. Three methods of measuring adherence readiness and their comparative utility in predicting early ART adherence were examined in a sample of 176 patients preparing to start ART. Data were analyzed data from a randomized controlled trial of a cognitive-behavioral adherence intervention. Three measures of pre-ART adherence readiness (provider estimate, 1 week vitamin practice trials, and self-report [HIV Medication Readiness Scale; Transtheoretical Stages of Change item (TSOC)] were examined in association with measures of (1) ART initiation, (2) ART retention, (3) mean electronic dose-taking adherence, and (4) achievement of optimal (85+ % dose-taking) adherence, over the first 3 months of ART. Of the 176 patients, 166 (94.3%) started ART; 124 (74.7% of those who started ART; 70.5% of whole sample) completed the first 3 months of ART. Among the 124 still on ART at month 3, mean dose-taking adherence was 79.3%, and 62 (35.2% of whole sample) achieved optimal adherence. The provider estimate was the only readiness measure significantly associated with each of the four measures of early ART adherence, and it had the highest concordance statistics (71% PPV and 62.3% NPV) with optimal early ART adherence. Practice trial adherence was only associated with ART initiation and retention. Dose-taking adherence over 3 months was significantly correlated with the provider estimate and the two self-reports. Each method of early treatment adherence has its own utility, but the provider estimate had the best overall performance in predicting early ART adherence.

Indexed as

Anti-HIV AgentsAntiretroviral Therapy, Highly ActiveCognitive Behavioral TherapyDrug MonitoringHIV InfectionsAdultFemaleHealth Knowledge, Attitudes, PracticeHumansMaleMiddle AgedRandomized Controlled Trials as TopicResearch DesignSelf ReportAnti-HIV AgentsAdherenceARTHIVSTARTTreatment readiness

Identifiers

PMID31650358
PMCPMC7862012

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.